Small Molecules

12 Feb 2019 Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
12 Feb 2019 Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
12 Feb 2019 Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
12 Feb 2019 European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
09 Feb 2019 NuvOx Pharma’s NVX-208 Shows Positive Results in Phase Ib/II Stroke Trial
07 Feb 2019 Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019
06 Feb 2019 FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
05 Feb 2019 Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
05 Feb 2019 FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam)
04 Feb 2019 Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant
04 Feb 2019 SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug
04 Feb 2019 Neurana Pharmaceuticals Announces First Patient Enrolled in the "STAR Study," a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back
04 Feb 2019 Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
04 Feb 2019 Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
04 Feb 2019 Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society’s Conference: Advances in Sleep and Circadian Science
02 Feb 2019 Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
01 Feb 2019 Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
01 Feb 2019 FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer
01 Feb 2019 Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States
01 Feb 2019 OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator
31 Jan 2019 Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute
31 Jan 2019 Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
31 Jan 2019 Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
30 Jan 2019 Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer
30 Jan 2019 Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up